PAVmed and its majority-owned digital health subsidiary Veris Health announced that Veris has been awarded a $1.8M grant from the National Institute on Minority Health and Health Disparities – NIMHD -, an institute of the National Institutes of Health – NIH -. The two-year grant will fund research to optimize and validate the Veris Cancer Care Platform for the needs of medically underserved cancer patients, in partnership with an academic cancer center. The research project will focus on patients facing language barriers, limited access to technology, and socioeconomic disparities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAVM:
- PAVmed announces efforts to regain Nasdaq compliance
- PAVmed’s Strategic Overhaul to Secure Nasdaq Compliance
- Lucid Diagnostics partnering with Front Line Mobile Health in esophageal cancer
- Atossa announces appointment of Parks as VP, Investor, Public Relations
- Lucid Diagnostics’ EsoGuard cancer diagnosis test highlighted in publication